Scandinavian ChemoTech announces that TSE™ therapy has been initiated at Ulis Medical Centre in Ukraine
After concluding the training of doctors, nurses and support staff at Ulis Medical Centre in Ukraine last week, the program started today and the first patient was treated.
Today the first treatment with Tumour Specific Electroporation - TSE™ was performed at Ulis Medical Centre in Ukraine to treat a woman with invasive squamous cell carcinoma (skin cancer). The therapy was performed with support from ChemoTech’s application team and ChemoTech’s Medical Adviser Dr. Suhail Mufti.
Since the treatment was performed under the intended use of TSE™, it is part of the general TSE™-program that has now started at the hospital and part of the commercial collaboration between ChemoTech and the hospital.
“It is really great to see that the hospital team so easily could perform the therapy under video guidance from our Applications team and that TSE now will be used on regular basis in Ukraine, one of the largest countries in Europe and a country that is in the process of becoming member state of the European Union”. Says Mohan Frick CEO and Co-Founder of ChemoTech
“We have performed the first Tumour Specific Electroporation in Ukraine. The procedure is easy to perform and well-controlled thanks to the specifics of the device. We have treated the patient with a locally advanced skin squamose-cell carcinoma. We are satisfied with the procedure and have positive expectations for the outcome for our patient. We consider this procedure as the best choice for the treatment of such cases.” says Professor Olexiy Kovalyov and Surgeon Andrey Ryaboshapka
For further information please contact: Mohan Frick, CEO
+46 (0)10-218 93 00
ir@chemotech.se
Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00, E-mail: certifiedadviser@penser.se
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation (TSE™), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se.
